Did the Pfizer CEO Get a Raise?
Yes. Albert Bourla's total compensation rose 12% to $27.6M in 2025, from $24.6M in 2024, per Pfizer's SEC DEF 14A filings.
This page answers a common executive-compensation question: Did the Pfizer CEO Get a Raise?. The answer draws on SEC DEF 14A proxy statements, the public disclosure mechanism for U.S. public-company executive pay. Every public company must file an annual proxy statement disclosing CEO and named-executive-officer compensation in detail. Why this matters for shareholders: executive compensation is the single most-disclosed governance metric at U.S. public companies, and the Dodd-Frank-mandated say-on-pay vote gives shareholders an explicit channel to express approval or dissent. Reading pay data well — including pay-versus-performance, peer-group selection, and time-vesting structures — is a basic part of stock-by-stock fundamental analysis.
The detailed answer below uses the actual proxy-statement filings, explains how to read them, and translates the executive-compensation accounting into the shareholder-relevant interpretation.
Albert Bourla Pay: 2024 → 2025
- 2025 total comp
- $27,585,301
- 2024 total comp
- $24,648,727
- Change ($)
- +$2,936,574
- Change (%)
- +12%
Source: Pfizer SEC DEF 14A proxy statements, 2024 and 2025 Summary Compensation Tables.
In its latest proxy statement, Pfizer reported Albert Bourla's 2025 total compensation at $27,585,301 — up $2,936,574 (12%) from $24,648,727 in 2024. The biggest single driver was stock awards, which fell $NaN.
Across the disclosed history, Albert Bourla's total pay has run: 2021, $24.4M; 2022, $33.0M; 2023, $21.6M; 2024, $24.6M; 2025, $27.6M. CEO compensation is lumpy year to year because equity grants — the largest component — are often awarded in multi-year blocks rather than evenly, so a single year's jump or drop can reflect grant timing as much as a change in pay philosophy.
Whether a raise is warranted ties back to performance: Pfizer posted a -4.2% three-year total shareholder return on 3.4% revenue growth, and the package carries a CEOPay Pay-for-Performance grade of C (61/100).
Compensation Detail
| Component | Amount |
|---|---|
| Total Compensation | $27,585,301 |
| Base Salary | $NaN |
| Stock Awards | $NaN |
| Option Awards | $NaN |
| Non-Equity Incentive | $NaN |
| CEO-to-Worker Pay Ratio | 276:1 |
| Pay-Performance Grade | C |
Other Pharmaceuticals CEOs
Frequently Asked Questions
Yes. Albert Bourla's total compensation rose 12% to $27.6M in 2025, from $24.6M in 2024, per Pfizer's SEC DEF 14A filings.
Albert Bourla, CEO of Pfizer, earned $27.6M in total compensation in 2025, including $NaNM in stock awards and $NaN in base salary.
In 2025, total compensation of $27,585,301 was composed of $NaN base salary, $NaN cash bonus, $NaN stock awards, $NaN option awards, and $NaN in non-equity incentive compensation.
Our Pay-for-Performance Score rates Pfizer as C (61/100), based on three-year total shareholder return of -4.2%, revenue growth of 3.4%, and shareholder say-on-pay vote approval.
Albert Bourla is the chief executive officer of Pfizer (PFE).
More about Pfizer
Yes. Albert Bourla's total compensation rose 12% to $27.6M in 2025, from $24.6M in 2024, per Pfizer's SEC DEF 14A filings.
Source: SEC EDGAR DEF 14A proxy statements, 2026.